Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry
On February 23, Piper Sandler boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $75 from $66 while keeping an Overweight rating on the company's shares.






